BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
301.53 USD
+1.67 (+0.56%)
301.53 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to BIO. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.97%, BIO is in line with its industry, outperforming 52.63% of the companies in the same industry.
BIO has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
BIO's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO outperforms 61.40% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO has a Operating Margin of 10.27%. This is in the better half of the industry: BIO outperforms 70.18% of its industry peers.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
The Gross Margin of BIO (52.42%) is better than 63.16% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
The number of shares outstanding for BIO has been reduced compared to 5 years ago.
The debt/assets ratio for BIO is higher compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 3.36. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIO (3.36) is better than 68.42% of its industry peers.
The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
BIO has a Debt to FCF ratio of 3.57. This is in the better half of the industry: BIO outperforms 77.19% of its industry peers.
BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.36 |
ROIC/WACC0.22
WACC10.09%
2.3 Liquidity
A Current Ratio of 5.44 indicates that BIO has no problem at all paying its short term obligations.
BIO's Current ratio of 5.44 is amongst the best of the industry. BIO outperforms 85.96% of its industry peers.
A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
BIO's Quick ratio of 3.94 is fine compared to the rest of the industry. BIO outperforms 70.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.90% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
The Revenue has decreased by -0.88% in the past year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.25 indicates a quite expensive valuation of BIO.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 75.44% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.38, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 29.04, the valuation of BIO can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 68.42% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (23.83), we can say BIO is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.25 | ||
| Fwd PE | 29.04 |
4.2 Price Multiples
78.95% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.15 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y0.36%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
301.53
+1.67 (+0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change1.8%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.13B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (20.09%)
Short Float %5.39%
Short Ratio4.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)14.15%
PT rev (3m)8.45%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)-2.34%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)3.75%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.25 | ||
| Fwd PE | 29.04 | ||
| P/S | 3.18 | ||
| P/FCF | 24.15 | ||
| P/OCF | 16.55 | ||
| P/B | 1.21 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.42%
EPS(NY)10.38
Fwd EY3.44%
FCF(TTM)12.48
FCFY4.14%
OCF(TTM)18.22
OCFY6.04%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.73
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.36 |
F-Score5
WACC10.09%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y15.44%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
What is the valuation status of BIO-RAD LABORATORIES-A (BIO) stock?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES-A (BIO) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 29.25 and the Price/Book (PB) ratio is 1.21.
What is the expected EPS growth for BIO-RAD LABORATORIES-A (BIO) stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -1.94% in the next year.